Holders — by stockHoldings — by fund
SAMSARA BIOCAPITAL, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001744967
$1.22B
disclosed book value
24
positions
31.2%
largest position share
Positions, as of 2026-06-30
top 24 of 24 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | SRRKSCHOLAR ROCK HLDG CORP | 6.9M | $379.4M | 31.2% |
| 2 | ALMSALUMIS INC | 6.3M | $178.6M | 14.7% |
| 3 | MLYSMINERALYS THERAPEUTICS INC | 5.9M | $158.4M | 13% |
| 4 | SEPNSEPTERNA INC | 3.1M | $105.5M | 8.7% |
| 5 | ALMRALAMAR BIOSCIENCES INC | 2.5M | $67.2M | 5.5% |
| 6 | NGNENEUROGENE INC | 1.7M | $54.0M | 4.4% |
| 7 | KLRSKALARIS THERAPEUTICS INC | 12.9M | $52.4M | 4.3% |
| 8 | SGPSPYGLASS PHARMA INC | 2.1M | $47.0M | 3.9% |
| 9 | STROSUTRO BIOPHARMA INC | 1.1M | $35.3M | 2.9% |
| 10 | IVAINVENTIVA SA | 6.3M | $23.9M | 2% |
| 11 | JBIOJADE BIOSCIENCES INC | 736,237 | $16.4M | 1.3% |
| 12 | PBLSPARABILIS MEDICINES INC | 556,044 | $15.2M | 1.3% |
| 13 | VTVTVTV THERAPEUTICS INC | 298,496 | $11.2M | 0.9% |
| 14 | AQSTAQUESTIVE THERAPEUTICS INC | 2.5M | $10.4M | 0.9% |
| 15 | NKTXNKARTA INC | 3.5M | $9.9M | 0.8% |
| 16 | ARTVARTIVA BIOTHERAPEUTICS INC | 954,861 | $9.3M | 0.8% |
| 17 | RANIRANI THERAPEUTICS HLDGS INC | 10.4M | $7.9M | 0.6% |
| 18 | AGMBAGOMAB THERAPEUTICS NV | 600,000 | $7.8M | 0.6% |
| 19 | ABVXABIVAX SA | 55,095 | $7.3M | 0.6% |
| 20 | XFORX4 PHARMACEUTICALS INC | 1.4M | $6.5M | 0.5% |
| 21 | ELOXELOXX PHARMACEUTICALS INC | 400,000 | $5.6M | 0.5% |
| 22 | CHRSCOHERUS ONCOLOGY INC | 3.4M | $4.8M | 0.4% |
| 23 | UPBUPSTREAM BIO INC | 353,717 | $2.4M | 0.2% |
| 24 | GOSSGOSSAMER BIO INC | 7.2M | $1.2M | 0.1% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.